Key Points {#FPar1}
==========

The current review examines the usefulness of pharmacologic treatments on improving cognitive function in persons with multiple sclerosis (MS).In conclusion, there is insufficient evidence to support the use of pharmacologic intervention to improve cognitive function in persons with MS.Higher-quality randomized controlled trials are needed to establish the cognitive efficacy of pharmacologic treatments for MS-related cognitive dysfunction, with cognition as the primary endpoint. Researchers are urged to use standardized criteria (such as the American Academy of Neurology criteria) to guide their research designs.Clinicians should consider effect sizes of studies before deciding whether to prescribe certain medications to ameliorate cognitive symptoms.

Introduction {#Sec1}
============

Multiple sclerosis (MS) is a progressive, autoimmune, inflammatory disease that affects myelination and axonal integrity in the central nervous system. Cognitive impairment occurs in approximately two-thirds of persons with MS \[[@CR1], [@CR2]\], most prominently in the domains of speed of information processing and learning and memory \[[@CR2], [@CR3]\]. Cognitive impairment can be extremely disruptive in symptom management, medication adherence, instrumental activities of daily living (e.g. managing finances, driving), employment, and independence among persons with MS \[[@CR3]--[@CR5]\]. Various medications have shown efficacy in reducing annualized relapse rates \[[@CR6]\], brain lesions as detected by magnetic resonance imaging \[[@CR7]\], and disability progression as determined by the Expanded Disability Status Scale \[[@CR8]\] among persons with MS; however, these metrics do not account for the hidden disabling symptoms of MS, such as fatigue and cognitive impairment. Moreover, cognitive endpoints traditionally have not been incorporated into phase III MS pharmaceutical trials, and, if they are, they are typically not primary endpoints. This results in studies that are underpowered and/or poorly designed for the purpose of examining cognitive outcomes. Therefore, our knowledge base regarding the efficacy of pharmacologic treatments on improving cognitive function in persons with MS is limited.

There is currently no standard intervention for cognitive impairment in MS, although research has been conducted investigating various pharmacologic, behavioral, and brain stimulation treatments. Specifically regarding medications, a 2013 Cochrane Review concluded that there is "no convincing evidence to support the efficacy of pharmacological symptomatic treatment for MS-associated memory disorder" due to the poor quality of extant literature \[[@CR9]\]. A more recent review published in 2016 similarly outlined methodological problems in pharmaceutical trials but argued that newer disease-modifying therapies (DMTs) and certain symptomatic therapies show promise in benefitting cognitive function \[[@CR10]\]. Both articles included only randomized controlled trials (RCTs), which are the gold standard in evaluating therapeutic effects. Neither article recommended any medication for standard clinical use of improving cognitive function due to the limitation of available evidence.

The current systematic review aimed to evaluate the efficacy of pharmacologic treatments in improving cognitive function among persons with MS, using the American Academy of Neurology (AAN) classification of evidence criteria and standardized effect size measures (when possible) for comparison across studies. Given the lack of established standard pharmacologic treatment for cognitive impairment in MS, and limited research base in general, we included *all* medications that were the subject of cognitive efficacy investigation in persons with MS, in order to present a comprehensive overview of the literature. Although the current review focused primarily on RCTs in establishing conclusions regarding various medications, a brief discussion of all relevant studies (including non-RCTs) was also included to address limitations of the literature as a whole.

Methods {#Sec2}
=======

A literature search was conducted of the PubMed and PsycINFO databases, using the following keywords: cognition, cognitive, neuropsychological, multiple sclerosis, disease modifying therapy, drug, medication, processing speed, attention, working memory, executive functioning, learning, and memory. Additionally, to identify abstracts that may not explicitly refer to cognition, particularly in studies where cognition is not the primary endpoint, 'PASAT' and 'SDMT' were used as keywords as they are the most commonly used tests in these studies \[[@CR11]\]. Only original, English-language research articles published in peer-reviewed journals between 1990 and January 2020 with human adult subjects were included in the current review. To be included, studies had to utilize at least one objective measure of cognition; studies using only subjective reports of cognition were excluded. Case studies, editorials, book chapters, and review articles were excluded, although citations in book chapters and review articles were cross-referenced and relevant articles were extracted. The initial search yielded 141 articles; 95 articles were screened based on the aforementioned inclusion and exclusion criteria, and a final sample of 87 articles were selected for final review (see Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Study selection process

Classification of evidence was determined using the 2017 AAN criteria for therapeutic trials \[[@CR12]\] (see electronic supplementary Table [1](#Tab1){ref-type="table"} for criteria). Four study authors reviewed the final sample of 87 articles using a structured review table and criteria. Each article was independently assessed by two reviewers who rated the article's classification of evidence. For each article, if there was disagreement, the two reviewers discussed their rationales and reached a consensus. If no consensus was reached, a third reviewer was asked to weigh in. Cohen's *d* was calculated as the measure of standardized effect size using a web calculator (<https://www.psychometrica.de/effect_size.html>) for RCTs and controlled studies. Effect sizes were only calculated for positive studies (i.e., studies indicating significant treatment effects). For studies that provided Cohen's *d*, the provided values were included in this review. For studies with unbalanced groups, we used modules \#2 and \#3 in the web calculator (analogous to Hedges' *g*), which corrected for the unequal sample sizes among groups. For small sample sizes (total sample size in both groups \[*n*\] \< 50), we multiplied the effect sizes by the bias correction factor (\[*n* − 3\]/\[*n* − 2.25\] × $\documentclass[12pt]{minimal}
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                \begin{document}$$\sqrt {\left[ {n - 2} \right]/n}$$\end{document}$). Data were treated parametrically, even in studies that utilized non-parametric tests (e.g. Wilcoxon signed-rank test) due to the lack of test statistics presented in most of these studies required to calculate non-parametric effect sizes. Repeated measures (e.g. pre- and post-treatment) were treated as independent measures (using module \#3 in the web calculator) because most studies did not provide correlation between pre- and post-treatment values, as was needed to account for repeated measure effects; calculation of Cohen's *d* based on the methods established by Morris and DeShon \[[@CR13], [@CR14]\] was used in these cases. Some studies did not provide sufficient information to calculate effect sizes, including studies that did not provide means and standard deviations (SDs) and studies that only provided medians and ranges/confidence intervals. Therefore, no effect sizes were provided for these studies.Table 1Summary of RCTs for disease-modifying therapiesAuthors (year)*N*Primary cognitive outcomesCognition as the primary endpoint?Main findingsEffect sizes for positive measuresAAN classificationComments*IFNs* *β-1a and 1b*Mokhber et al. (2014) \[[@CR15]\]63 RRMS patients (comparators = IFNs β-1a and 1b)BRNBYesIFN β-1a (Avonex and Rebif) groups significantly improved on more measures (six and five of eight, respectively) than the IFN β-1b (Betaferon) group (one of eight) after 1 yearCompared with Betaferon, Cohen's *d* = 0.04--0.25 for Avonex and 0.02--0.36 for Rebif (mean = 0.16)Class IIMore than two primary endpoints*IFN* *β-1a*Cohen et al. (2002) \[[@CR17]\]436 SPMS patients (comparator = placebo)PASATNoTrend of improvement after 2 years of treatment relative to the placebo groupCohen's *d* = 0.20Class IIIMPACT trial; met class I criteria but downgraded because cognition was not the sole primary endpoint*IFN* *β-1b*Montalban et al. (2009) \[[@CR21]\]73 primary or transitional progressive MS patients (comparator = placebo)BRNBNoNo significant differences between groups after 2 years of treatmentNAClass IIUnclear if allocation was concealedPenner et al. (2012) \[[@CR22]\]439 originally CIS patients (comparator = placebo)PASATNo*RCT phase*: Significant improvement after 2 years of treatment relative to the placebo group*Open-label phase*: At year 5 (3 years after the double-blind phase ended), the early treatment group (previously in the treatment group) had a higher score increase than the delayed treatment group (previously in the placebo group)Cohen's *d* = 0.23 at year 2Cohen's *d* = 0.32 at year 5Class IIBENEFIT trial; secondary analysis of a previous study that did not a priori define cognitive endpoints*Glatiramer acetate*Weinstein et al. (1999) \[[@CR26]\]248 RRMS patients (comparator = placebo)BRNBNoNo significant treatment effect after 24 monthsNAClass IISecondary analysis of previous study that did not a priori define cognitive endpoints; current study did not specify primary endpoints*Fingolimod*Kappos et al. (2016) \[[@CR45]\]1556 RRMS patients (subset of original trials: lower-dose vs. placebo groups)---first 6 months of data (comparator = placebo)PASATNoSignificant improvement after 6 months of treatment relative to the placebo groupCohen's *d* = 0.13Class IIFREEDOMS and FREEDOMS II trials; secondary analysis of a previous study that did not a priori define cognitive endpointsComi et al. (2017) \[[@CR46]\]157 RRMS patients with ≥ 1 test of BRNB of scores \<10th percentile (comparator = IFN β-1b)BRNB and D-KEFS Sorting TestPrimary endpoint not specifiedNo significant differences between groups after 18 months of treatmentNAClass IIIOpen-label, rater-blinded GOLDEN trial; authors noted an imbalance in baseline characteristics and dropout pattern may have favored the comparator group*Daclizumab* *β*Benedict et al. (2018) \[[@CR47]\]1841 RRMS patients (comparator = IFN β-1a)SDMTNoSignificant improvement but negligible treatment effect relative to the IFN group after 96 and 144 weeksCohen's *d* = 0.11 at week 96; week 144 data were omitted because they were only 33% of the originally randomized sampleClass IIDECIDE trial; secondary analysis of RCT that did not a priori define cognitive endpoints; drug discontinued by drug companies due to reports of encephalitis in EuropeEffect sizes were only calculated for studies with positive findings; some effect sizes could not be calculated due to insufficient data provided in the papers. The total number of cognitive measures was determined by what the authors presented in their Results sections; multiple scores from a cognitive test count as multiple measures (e.g. immediate recall, delayed recall, and recognition of a memory test)*AAN* American Academy of Neurology, *BRNB* Brief Repeatable Neuropsychological Battery, *CIS* clinically isolated syndrome, *D-KEFS* Delis--Kaplan Executive Function System, *IFN* interferon, *MS* multiple sclerosis, *NA* not available, *PASAT* Paced Auditory Serial Addition Test, *RCT* randomized controlled trial, *RRMS* relapsing-remitting multiple sclerosis, *SDMT* Symbol Digit Modalities Test, *SPMS* secondary-progressive multiple sclerosis

Results {#Sec3}
=======

Eighty-seven articles published between 1990 and January 2020 were included in this review. For classification of evidence using the AAN criteria, reviewers disagreed on 31 articles, of which they were able to reach a consensus after discussion on 30 articles, and a third reviewer weighed in for one article. The medications were divided into three categories for the purpose of this review: DMTs, symptomatic therapies, and other therapies. The efficacy of these medications on cognitive function was reviewed. For brevity, this review analyzed only the primary cognitive endpoints if the studies specified them. A study was considered negative if the treatment effect was found on a secondary endpoint but not a primary endpoint. If primary endpoints were not specified, all cognitive endpoints were analyzed; however, the lack of a primary endpoint specification would be noted as a weakness, which would downgrade the AAN classification of evidence. Secondary analyses of RCTs that only included a subset of the original treatment allocation groups were designated as class III due to increased participant selection bias (i.e. not all participants had equal opportunity to be allocated to each group). As a general trend, the proportion of positive studies (i.e. findings of significant drug efficacy) tended to increase as the quality of evidence (AAN classifications) decreased. Indeed, class IV observational studies consisted of the highest number of positive studies (number of positive studies: class IV = 33; class III = 24; class II = 24; class I = 6) (see Fig. [2](#Fig2){ref-type="fig"}). The following sections discuss each medication in detail individually, with an emphasis on RCTs. Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"} summarize the main findings, effect sizes, and evidence classifications of the studies reviewed. Data are divided into RCTs (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}), non-randomized, controlled/quasi-controlled studies (Table [4](#Tab4){ref-type="table"}), and observational studies (Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}).Fig. 2Number of positive studies, stratified by **A** study type and **B** AAN class of evidence. The proportion of positive studies increased as the quality of evidence decreased. *AAN* American Academy of NeurologyTable 2Summary of RCTs for symptomatic treatmentsAuthors (year)*N*Primary cognitive outcomesCognition as the primary endpoint?Main findingsEffect sizes for positive measuresAAN classificationComments*Dalfampridine*De Giglio et al. (2019) \[[@CR48]\]120 MS patients with an SDMT score \< 10th percentile (comparator = placebo)SDMTYesSignificant improvement after 12 weeks of treatment relative to the placebo group; no significant difference between groups at 4-week follow-up (washout period)Cohen's *d* = 0.60 for raw scores; Cohen's *d* = 0.61 for z scores^a^Class IArreola-Mora et al. (2019) \[[@CR49]\]21 RRMS patients (comparator = placebo)Study-specific neuropsychological batteryYesSignificant improvement after 20 weeks of treatment relative to the placebo group, on 12 of 35 measuresCohen's *d* = 0.18--0.46 (mean = 0.38)Class IIDid not specify the primary endpointsSatchidanand et al. (2020) \[[@CR50]\]57 MS patients with at least 1.5 SD below the mean on one domain or informant report of cognitive impairmentSDMTYesNo significant treatment effect on SDMT relative to placebo after 12 weeks; responders improved on one of the secondary endpoints PASAT but not the primary endpoint SDMTNAClass IINo description regarding determination of cognitive impairment using objective measures or a randomization/blinding procedureBroicher et al. (2018) \[[@CR51]\]20 MS patients completed the crossover RCT phase (comparator = placebo); 2 weeks for each condition (2-week washout period)Study-specific neuropsychological batteryPrimary endpoint not specified*RCT phase*: Participants performed better under the treatment condition than the placebo condition on 1 of 8 measuresInsufficient dataClass IIIFAMPKIN extension trial; did not compare baseline characteristics between treatment order groups, or examine carryover effects; study authors classified the study as class IISmits et al. (1994) \[[@CR52]\]20 MS patients (crossover; comparator = placebo); 2 weeks for each condition (2-week washout period)BRNB, computerized test adapted from CVLTYesNo significant improvement during the treatment condition relative to the placebo conditionNAClass IIITreatment/placebo group had higher EDSS and lower SDMT than the placebo/treatment group at baseline; more than two primary endpoints specified*Donepezil*Krupp et al. (2004) \[[@CR59]\]68 MS patients with an RAVLT score at least 0.5 SD below the mean, but an MMSE score ≥ 26 (comparator = placebo)SRT total recallYesSignificant improvement after 24 weeks of treatment relative to placeboCohen's *d* = 0.50^a^Class IKrupp et al. (2011) \[[@CR60]\]120 MS patients with an RAVLT score at least 0.5 SD below the mean (comparator = placebo)SRT total recallYesNo significant treatment effect after 24 weeksNAClass I*Rivastigmine*Shaygannejad et al. (2008) \[[@CR61]\]60 MS patients with at least mild verbal memory impairment as indicated by the WMS (comparator = placebo)WMS general memory scoreYesNo significant treatment effect after 12 weeksNAClass IHuolman et al. (2011) \[[@CR62]\]15 MS patients (comparator = placebo)Modified PASAT for fMRINoSignificant improvement relative to the placebo groupCohen's *d* = 0.25Class IIDid not specify the primary endpointMäurer et al. (2013) \[[@CR63]\]81 MS patients with a Faces Symbol Test score ≥ 3 and/orMultiple Sclerosis Inventory Cognition score ≤ 19 (comparator = placebo)SRTYesNo significant treatment effect after 16 weeksNAClass IIInitially planned to recruit 200 patients but were only able to recruit 86 patients; changes made after randomization regarding eligibility criteria, sample size, and duration of follow-upCader et al. (2009) \[[@CR64]\]15 MS patients with subjective cognitive complaints; crossover (treatment = rivastigmine + domperidone; comparator = domperidone); no washout periodBRNBNoNo significant treatment effect after 4 weeksNAClass IIIInvestigator-blind; baseline characteristics were not presented; 71% of enrolled participants completed the study*Memantine*Saint Paul et al. (2016) \[[@CR66]\]62 RRMS patients with a Dementia Rating Scale score ≥ 130 and PASAT \> 15, but 1.5 SD below the mean (comparator = placebo)PASATYesNo significant treatment effect after 52 weeksNAClass IIEMERITE trial; only 67% of participants completed the study; discontinued participants were younger and had a better baseline PASAT scoreLovera et al. (2010) \[[@CR65]\]114 MS patients with a PASAT or CVLT-II long-delay free recall of at least 1 SD below the mean (comparator = placebo)PASAT, CVLT-II long-delay free recallYesNo significant treatment effect after 16 weeksNAClass IIITreatment group had a higher proportion of progressive subtypes and lower baseline CVLT-II score*Gingko biloba*Lovera et al. (2007) \[[@CR68]\]38 MS patients with a PASAT or CVLT-II total score 0.5--2.5 SD below the mean (comparator = placebo)Study-specific neuropsychological batteryYesNo significant treatment effect after 12 weeksNAClass IIMore than two primary endpoints specifiedLovera et al. (2012) \[[@CR67]\]120 MS patients with scores of 1 SD below the mean on the Stroop test, CVLT-II, COWAT, and PASAT (comparator = placebo)Study-specific neuropsychological batteryYesNo significant treatment effect after 12 weeksNAClass IIMore than two primary endpoints specified; authors classified the study as class IDiamond et al. (2013) \[[@CR69]\]21 MS patients (comparator = placebo)Study-specific neuropsychological batteryNoSignificantly faster processing speed and fewer intrusions on verbal learning after 4 weeks of treatment relative to the placebo group (unclear how many total measures were examined due to limited content in the short report)Cohen's *d* = 0.55 for speed and Cohen's *d* = 0.78 for intrusionsClass IIISecondary analysis of a previous study that did not a priori define cognitive endpoints; more than two primary endpoints were specified in the current study; limited description of study procedures and results due to the short report format[l]{.smallcaps}-*Amphetamine sulfate*Morrow et al. (2009) \[[@CR70]\]136 MS patients with an SDMT 1.5 SD below the mean or CVLT-II total or delayed recall or PASAT 1 SD below the mean (comparator = placebo)SDMTYesNo significant treatment effect after 29 days, on the SDMT; significant treatment effect on secondary measures of BVMT-R and CVLT-II delayed recallNAClass ISumowski et al. (2011) \[[@CR71]\]136 MS patients (comparator = placebo)CVLT-II and BVMT-R delayed recallYesSignificant improvement in baseline-impaired patients treated with [l]{.smallcaps}-amphetamine for 29 days, relative to the placebo and baseline-intact groups, on CVLT-II and BVMT-R (impairment based on median split)Treatment---placebo, Cohen's *d* = 0.94 for CVLT-II and *d* = 1.00 for BVMT-R among baseline-impairedClass IIRe-analysis of the Morrow et al. study \[[@CR70]\] (see Table [3](#Tab3){ref-type="table"}); original study did not target memory-impaired participantsBenedict et al. (2008) \[[@CR72]\]19 MS patients with CVLT-II, SDMT, or PASAT 1 SD below the mean (crossover; comparator = placebo); single dose of 15, 30, or 45 mg (1-week washout period)Study-specific neuropsychological batteryYesSignificantly better performance on processing speed measures under 45 mg treatment compared with placebo conditions; no significant findings for memory measuresCohen's *d* = 0.36--0.45 (mean = 0.41)Class IIIDid not compare baseline characteristics of the treatment order groups or examine carryover effects; more than two primary outcomes*Mixed amphetamine salts containing dextroamphetamine, amphetamine,*[d]{.smallcaps}*-amphetamine, and*[d]{.smallcaps}--[l]{.smallcaps}*-amphetamine aspartate monohydrate*Morrow and Rosehart (2015) \[[@CR73]\]49 MS patients with scores of 1.5 SD below the mean on SDMT or PASAT (comparator = placebo); single dose of 5 or 10 mgSDMT, PASATYesSignificant improvement on SDMT after a single dose of 10 mg relative to placeboCohen's *d* = 0.47^a^Class I*Methylphenidate*Harel et al. (2009) \[[@CR75]\]26 RRMS patients with PASAT \< 25th percentile (comparator = placebo)PASATYesSignificant improvement after a single dose of drug relative to the placebo groupCohen's *d* = 0.52 for 3″ and *d* = 0.71 for 2″Class IIThe authors did not provide detailed information about randomization and blinding (unclear about concealed allocation)*Lisdexamfetamine dimesylate*Morrow et al. (2013) \[[@CR74]\]63 MS patients with SDMT or PASAT 1.5 SD below the mean (comparator = placebo)SDMT, PASATYesSignificant improvement on SDMT after 4 weeks of treatment up to the highest tolerable dose relative to placebo group; SDMT score remained stable for another 4 weeks of treatment; no significant findings for PASATCohen's *d* = 0.60Class IIThe treatment group had lower SDMT and BVMT-R scores at baseline, not controlled in the analyses; 76% dropout rate*Modafinil*Mőller et al. (2011) \[[@CR76]\]121 MS patients with a Fatigue Severity Scale score ≥ 4SDMT, PASATNoContradictory findings that did not favor one groupNAClass IIDid not provide detailed information regarding blindingFord-Johnson et al. (2016) \[[@CR77]\]16 MS patients with a score of 1.5 SD below the mean on Open-Trial SRT (crossover; comparator = placebo); 2 weeks for each condition (1-week washout period)CVLT-IIYesNo significant change on CVLT-II; significant improvement relative to placebo on one of six secondary outcomes (of 11 measures in total)NAClass IIGiven significant carryover effects, only between-subject analysis of the first 2 weeks of data was included; more than two primary outcomes*Armodafinil*Bruce et al. (2012) \[[@CR78]\]30 MS patients with an SDMT score 1 SD below the mean (crossover; comparator = placebo); single dose (1-week washout period)Study-specific neuropsychological batteryYesSignificant improvement on one of eight measures: RAVLT delayed recallCohen's *d* = 1.33Class IIDid not specify primary outcomes*Amantadine*Sailer et al. (2000) \[[@CR80]\]24 MS patients with a Fatigue Severity Scale score \> 4 (crossover; comparator = placebo; 10-day washout period)Reaction time taskNoNo significant treatment effect relative to placebo condition after 10 daysNAClass IIINo details about dropouts; no direct comparison of treatment order groups for baseline measures; two treatment order groups differed in the main efficacy analysisEffect sizes were only calculated for studies with positive findings; some effect sizes could not be calculated due to insufficient data provided in the papers. The total number of cognitive measures was determined by what the authors presented in their "[Results](#Sec3){ref-type="sec"}" sections; multiple scores from a cognitive test count as multiple measures (e.g. immediate recall, delayed recall, and recognition of a memory test)*AAN* American Academy of Neurology, *BRNB* Brief Repeatable Neuropsychological Battery, *BVMT-R* Brief Visual Memory Test, *COWAT* Controlled Oral Word Association Test, *CVLT* California Verbal Learning Test, *CVLT-II* California Verbal Learning Test, 2nd Edition, *EDSS* Expanded Disability Status Scale, *fMRI* functional magnetic resonance imaging, *MMSE* Mini-Mental State Examination, *MS* multiple sclerosis, *NA* not available, *PASAT* Paced Auditory Serial Addition Test, *RAVLT* Rey Auditory Verbal Learning Test, *RCT* randomized controlled trial, *RRMS* relapsing-remitting multiple sclerosis, *SD* standard deviation, *SDMT* Symbol Digit Modalities Test, *SRT* Selective Reminding Test, *WMS* Wechsler Memory Scale^a^ Effect sizes provided by the study authorsTable 3Summary of RCTs for other treatmentsAuthors (year)*N*Primary cognitive outcomesCognition as the primary endpoint?Main findingsEffect sizes for positive measuresAAN classificationComments*Recombinant human erythropoietin* (*EPO*)Schreiber et al. (2017) \[[@CR82]\]50 progressive MS patients (comparator = placebo)TMT Part BNoNo significant differences between groups after 24 weeksNAClass IIMet the class I criteria but downgraded because cognition was not the sole primary outcomeEhrenreich et al. (2007) \[[@CR95]\]Eight chronic progressive MS patients who previously did not respond to DMTs: 5 in the high-dose group (48,000 IU) and three in the low-dose group (8000 IU)Study-specific neuropsychological batteryPrimary endpoint not specifiedThe high-dose group significantly improved on 7 of 13 measures after 24 weeks of treatment; the low-dose group did not improve over 12 weeks of treatmentFrom the table in the electronic supplementary material, at 12 weeks, treatment effect (high-dose vs. low-dose): Cohen's *d* = − 0.063 to 2.012 (mean = 0.82)Class IVOpen-label; authors did not directly compare the high-dose and low-dose groups after 12 weeks of treatment (last time point when data were available for both groups); no inclusion of baseline comparison between the groups*Simvastatin*Chan et al. (2017) \[[@CR83]\]140 SPMS patients not treated with DMTs (comparator = placebo)Study-specific neuropsychological batteryNoSignificant improvement after 24 months of treatment compared with placebo on one screening measure of 15 total measuresInsufficient dataClass IIMS-STAT trial; study did not specify the primary outcomes*Atorvastatin*Lanzillo et al. (2016) \[[@CR84]\]154 RRMS patients (comparator = placebo)BRNBNoNo significant treatment effect after 24 monthsNAClass IILarge dropout rate; only 63% of the original randomized patients were analyzed for cognitive data*Estrogen*De Giglio et al. (2017) \[[@CR85]\]142 female RRMS patients (comparators: IFN β-1a with 20 μg estrogen, IFN β-1a with 40 μg estrogen, or IFN β-1a)BRNB: proportion of people with at least two test scores that were 1 SD below the meanNoAt month 24, the high-dose estrogen group had significantly fewer patients with cognitive impairment than the IFN-only group, and lower risk of developing cognitive impairmentOdds ratio for the high-dose estrogen group's reduced risk of cognitive impairment = 0.27^a^Class IIDid not specify the primary outcomesEffect sizes were only calculated for studies with positive findings; some effect sizes could not be calculated due to insufficient data provided in the papers. The total number of cognitive measures was determined by what the authors presented in their Results sections; multiple scores from a cognitive test count as multiple measures (e.g. immediate recall, delayed recall, and recognition of a memory test)*AAN* American Academy of Neurology, *BRNB* Brief Repeatable Neuropsychological Battery, *DMTs* disease-modifying therapies, *IFN* interferon, *MS* multiple sclerosis, *NA* not available, *RCT* randomized controlled trial, *RRMS* relapsing-remitting multiple sclerosis, *SD* standard deviation, *SPMS* secondary-progressive multiple sclerosis, *TMT* Trail-Making Test^a^Effect sizes provided by the study authorsTable 4Summary of non-randomized, controlled studies (class III)Authors (year)*N*Primary cognitive outcomeCognition as the primary endpoint?Main findingsEffect sizes for positive measuresComments**Disease-modifying therapies***IFNs* *β-1a and 1b*Melanson et al. (2010) \[[@CR16]\]40 RRMS patients (comparators = IFN β-1a and IFN β-1b)BRNBYes (along with fatigue as the co-primary endpoint)No significant differences among groups after 6 and 12 months of treatmentNA*IFN* *β-1a*Fischer et al. (2000) \[[@CR18]\]166 RRMS patients (comparator = placebo; part of a larger RCT)Composite scores: (a) information processing and learning/memory; (b) visuospatial and problem-solving; (c) verbal and attention (guided by factor analysis)NoSignificant improvement after 2 years of treatment, on information processing and learning/memoryInsufficient data*IFN β-1b*Pliskin et al. (1996) \[[@CR24]\]30 MS patients (comparator = placebo; part of a larger RCT)Study-specific neuropsychological batteryNoSignificant improvement in the high-dose treatment group over 2 years (year 2 to year 4) relative to other groups (low-dose and placebo) on 1 of 12 measuresHigh-dose: Cohen's *d* = 0.59 relative to the low-dose treatment group; *d* = 0.91 relative to the placebo groupBarak and Achiron (2002) \[[@CR23]\]46 RRMS patients (comparator = untreated RRMS patients matched on the EDSS)BRNBYesSignificant improvement in the treatment group after 1 year on three of six measures; significant decline on three of six measures in the comparator groupTreatment effect relative to the comparator group: Cohen's *d* = 0.40--8.05 (mean = 2.63)Two groups had comparable performances at 1-year follow-up; treatment effects were driven by lower performance in the treatment group at baselineSelby et al. (1998) \[[@CR96]\]167 RRMS patients (comparator = waitlist)Study-specific neuropsychological batteryYesNo significant cross-sectional differences between groupsNA*Glatiramer acetate*Vacaraş et al. (2014) \[[@CR27]\]37 RRMS with 3--4 years disease course and drug-naive (comparator = placebo)PASAT and MoCANoThe treatment group significantly improved on PASAT after 1 year, while the placebo group significantly declined. The treatment group did not improve on MoCA, and the placebo group declinedInsufficient dataDid not note randomization or blindingYtterberg et al. (2007) \[[@CR28]\]83 MS patients; all started with monotherapy (glatiramer acetate or IFN β); 21 patients switched to combination therapy (glatiramer acetate + IFN β) due to worsening of MS symptomsSDMTNoNo significant differences between the monotherapy (glatiramer acetate or IFN β for 24 months) and combination therapy (glatiramer acetate and IFN β for 16--24 months) groups; did not compare between two monotherapy groupsNA*Natalizumab*Weinstock-Guttman et al. (2012) \[[@CR32]\]942 RRMS patients (comparator = placebo; part of a larger RCT)Onset of 0.5 SD decline on PASAT sustained for 12 weeksNoSignificantly reduced risk of cognitive decline after 2 years relative to the placebo group in the AFFIRM trial; no significant reduction in the SENTINEL trialHazard ratio = 0.57^a^Results from the AFFIRM and SENTINEL trials; unclear if the two groups were matchedRorsman et al. (2018) \[[@CR35]\]34 RRMS patients with at least one measure of 2 SDs below the mean or two measures of 1 SD below the mean (comparator = stable MS patients receiving other DMTs)MACFIMSYesBetween-subject: Significant improvement after 1 year of treatment relative to quasi-controls on PASAT (1 of 10 measures). Within-subject: Significant improvement in the treatment group on 4 of 10 measures, but not in quasi-controlsInsufficient dataQuasi-controls had higher SDMT scores and longer illness duration; a higher proportion of the natalizumab group had a relapse within the past 6 months, and lesionsMattioli et al. (2011) \[[@CR34]\]24 RRMS patients (comparator = stable MS patients taking other DMTs)Study-specific neuropsychological batteryYesBetween-subject: Significant improvement after 1 year of treatment, relative to the placebo group, on delayed visual memory composite (1 of 10 measures)Within-subject: Significant improvement in the treatment group on 3 of 10 measures, and no significant change in the quasi-comparator groupInsufficient dataThe natalizumab group had significantly more relapses in the previous year than the quasi-comparator groupSundgren et al. (2016) \[[@CR97]\]30 RRMS patients (comparator = stable MS patients receiving other DMTs)Study-specific neuropsychological batteryYesNo significant differences between groups after 1 year of treatmentNAThe natalizumab group had significantly higher EDSS and non-significant higher disease duration than the quasi-comparator groupIaffaldano et al. (2016) \[[@CR36]\]58 RRMS patients (comparator = patients who stopped treatment)CII = as impaired; index based on the number of SDs below the mean on individual tests from the BRNB and Stroop testYesSignificant increase in CII among interrupters after 1 year of discontinuation, and decrease in continuersReduction of CII in continuers compared with interrupters: Cohen's *d* = − 0.62*Mitoxantrone*Schröder et al. (2011) \[[@CR98]\]26 progressive or relapsing-progressive MS patients (comparator = MS patients who met the criteria for therapy but did not receive treatment)Study-specific neuropsychological batteryYesNo significant change in the treatment group after 2 years; the comparator group had reduced performance on two of seven measuresInsufficient dataIt was noted that the comparator group did not receive treatment due in part to cardiac contraindications; the comparator group was significantly smaller (*n* = 6)**Symptomatic treatments***Modafinil*Lange et al. (2009) \[[@CR79]\]21 MS patients with an FSS sum score ≥ 36 (comparator = placebo; part of a larger RCT)d2 alertness testNoSignificant reduction in errors in the treatment group after 3 h and 8 weeks of treatment; no change in the placebo groupInsufficient data*Amantadine*Geisler et al. (1996) \[[@CR81]\]45 Ambulatory MS patients with FSS ≥ 4 (part of a larger RCT)Study-specific neuropsychological batteryNoNo significant differences among the amantadine, pemoline, or placebo groups after 6 weeksNAMore than two primary outcomes specified**Other treatments***Methylprednisolone*Patzold et al. (2002) \[[@CR86]\]37 MS patients (comparators: 27 with acute exacerbation and 10 without acute exacerbation)PASATNoSignificant improvement after 19 days of treatment; no significant change in the quasi-control groupCohen's *d* = 0.36Effect sizes were only calculated for studies with positive findings; some effect sizes could not be calculated due to insufficient data provided in the papers. The total number of cognitive measures was determined by what the authors presented in their Results sections; multiple scores from a cognitive test count as multiple measures (e.g. immediate recall, delayed recall, and recognition of a memory test)*BRNB* Brief Repeatable Neuropsychological Battery, *CII* Cognitive Impairment Index, *DMTs* disease-modifying therapies, *EDSS* Expanded Disability Status Scale, *FSS* Fatigue Severity Scale, *IFN* interferon, *MACFIMS* Minimal Assessment of Cognitive Function in Multiple Sclerosis, *MoCA* Montreal Cognitive Assessment, *MS* multiple sclerosis, *NA* not available, *PASAT* Paced Auditory Serial Addition Test, *RCT* randomized controlled trial, *RRMS* relapsing-remitting multiple sclerosis, *SD* standard deviation, *SDMT* Symbol Digit Modalities Test^a^Effect sizes provided by the study authorsTable 5Summary of all other observational studies (class IV) for disease-modifying therapiesAuthors (year)*N*Primary cognitive outcomeCognition as the primary endpoint?Main findingsComments*IFN* *β-1a*Patti et al. (2010) \[[@CR20]\]318 treatment-naive RRMS patients (comparators: 44 µg and 22 µg)Proportion of patients with cognitive impairment (based on 1 SD below the mean on ≥ 3 tests of the BRNB and Stroop test)Yes32% significant risk reduction in the 44 µg vs. 22 µg groups; the 44 µg group had a significantly lower risk of cognitive impairment at year 3 relative to 22 µg groupCOGIMUS trialPatti et al. (2013) \[[@CR19]\]133 treatment-naive RRMS patients (comparators: 44 µg and 22 µg)Proportion of patients with cognitive impairment (based on 1 SD below the mean on ≥ 3 tests of the BRNB and Stroop test)YesThe 44 µg group had a significantly lower risk of cognitive impairment than the 22 µg group2-Year extension study after the original COGIMUS trial; patients continued the same treatment dose*IFN* *β-1b*Tur et al. (2011) \[[@CR101]\]59 PPMS patientsBRNBNoAfter 5 years without treatment, the original treatment group performed significantly better than the original placebo group, on one of six measuresFollow-up of the study by Montalban et al. \[[@CR21]\] (placebo-controlled RCT; see Table [3](#Tab3){ref-type="table"})Edan et al. (2014) \[[@CR99]\]464 originally CIS patients; some converted to MSPASATNoAt year 8 (6 years after the double-blind phase ended), the early treatment group (previously in the treatment group) had a higher score increase than the delayed treatment group (previously in the placebo group)Follow-up of BENEFIT (placebo-controlled RCT; see Penner et al. \[[@CR22]\]; see Table [3](#Tab3){ref-type="table"})Kappos et al. (2016) \[[@CR100]\]278 originally CIS patients; some converted to MSPASATNoAt year 11 (9 years after the RCT ended), the early treatment group (previously in the treatment group) had a higher score increase than the delayed treatment group (previously in the placebo group)Follow-up of BENEFIT (placebo-controlled RCT; see Penner et al. \[[@CR22]\]; see Table [3](#Tab3){ref-type="table"})Flechter et al. (2007) \[[@CR25]\]15 MS patientsWCST perseverative response scoreYesSignificant improvement after 1 yearLacy et al. (2013) \[[@CR103]\]16 RRMS patientsStudy-specific neuropsychological batteryYesAt year 16 relative to year 2, no consistent pattern of change in the overall cohort or previous treatment allocation groupsFollow-up of placebo-controlled RCT; study attributed stability of cognition to benefit of drugGerschlager et al. (2000) \[[@CR102]\]14 MS patients treated with IFN, and 14 healthy participantsStudy-specific neuropsychological batteryNoSimilar pattern of improvement in MS patients and healthy participants after 1 year*Glatiramer acetate*Schwid et al. (2007) \[[@CR104]\]153 MS patientsBRNBNo10 Years after the RCT, no significant differences between the original treatment allocation groupsFollow-up of a placebo-controlled RCTZiemssen et al. (2014) \[[@CR29]\]72 RRMS patientsPASATNoSignificant improvement after 2 years of treatmentCOPTIMIZE trialZiemssen et al. (2015) \[[@CR31]\]668 RRMS patientsPASATNoSignificant improvement after 2 years of treatmentCOPTIMIZE trialZiemssen et al. (2016) \[[@CR30]\]MS patients (370 had PASAT data; 453 had MUSIC data)PASAT and MUSIC scalesNoSignificant improvement after 2 years of treatmentQualiCOP trial*Natalizumab*Iaffaldano et al. (2012) \[[@CR43]\]100 RRMS patients (53 completed 2 years)CII based on the number of SDs below the mean on individual tests from the BRNB and Stroop testYesSignificant reduction of CII after 1 and 2 years of treatmentIaffaldano et al. (2014) \[[@CR38]\]42 RRMS patients (21 completed 2 years)CII based on the number of SDs below the mean on individual tests from the BRNB and Stroop testYesSignificant reduction of CII after 1 year of treatment; significant reduction of CII after 2 years of treatmentMattioli et al. (2011) \[[@CR37]\]39 RRMS patients (11 with year 2 data)Study-specific neuropsychological batteryYesSignificant improvement after 1 and 2 years of treatment, on 3 of 13 measures (different three measures for each year; *p* \< 0.001 to 0.048)Mattioli et al. (2015) \[[@CR44]\]24 RRMS patientsStudy-specific neuropsychological batteryYesSignificant reduction in the number of impaired neuropsychological tests (2 SDs below the mean) over 3 years of treatmentWilken et al. (2013) \[[@CR41]\]89 RRMS patientsAutomated Neuropsychological Assessment MetricsNoSignificant improvement after 2 years of treatment, on two of three indicesENER-G trialLang et al. (2012) \[[@CR39]\]29 MS patients after other DMTs have failedStudy-specific neuropsychological batteryPrimary endpoint not specifiedSignificant improvement on 3 of 14 measures over 6 months of treatmentPerumal et al. (2019) \[[@CR42]\]RRMS patients with diagnosis \< 3 years (191 treated for 1 year; 158 treated for 2 years)SDMTNoSignificant improvement on SDMT after 1 and 2 years of treatmentSTRIVE trialNovakova et al. (2015) \[[@CR40]\]31 RRMS patientsSDMTNoSignificant improvement after 1 year of treatment*Teriflunomide*Coyle et al. (2017) \[[@CR105]\]1000 RRMS patientsSDMTNoNo significant improvement after 48 weeks of treatment*Alemtuzumab*Fox et al. (2012) \[[@CR106]\]45 RRMS patientsPASATNoPatients were seven times more likely to improve or remain stable than to decline after 1 year*BRNB* Brief Repeatable Neuropsychological Battery, *CII* Cognitive Impairment Index, *CIS* clinically isolated syndrome, *DMTs* disease-modifying therapies, *IFN* interferon, *MS* multiple sclerosis, *MUSIC* Multiple Sclerosis Inventory Cognition, *PASAT* Paced Auditory Serial Addition Test, *PPMS* primary-progressive multiple sclerosis, *RCT* randomized controlled trial, *RRMS* relapsing-remitting multiple sclerosis, *SD* standard deviation, *SDMT* Symbol Digit Modalities Test, *WCST* Wisconsin Card Sorting TestTable 6Summary of all other observational studies (class IV) for symptomatic and other treatmentsAuthors (year)*N*Primary cognitive outcomeCognition as the primary endpoint?Main findingsComments**Symptomatic treatments***Dalfampridine*Korsen et al. (2017) \[[@CR53]\]34 MS patients with impaired mobilityPASATNo primary endpoint specifiedSignificant improvement for the entire cohort; responder status did not predict cognitive changeTriche et al. (2016) \[[@CR55]\]39 MS patients newly prescribed dalfampridine: 31 were treated with drug for 14 weeks or longer, and 8 discontinued drug before 14 weeksSDMTNo primary endpoint specifiedSignificant improvement on SDMT in patients treated for at least 14 weeks, but only patients who were respondersMagnin et al. (2015) \[[@CR54]\]50 MS patientsLetter fluency ("p") and semantic (animal) fluency for 120″YesLetter fluency significantly improved after 14 days and 21 days of treatment; semantic fluency significantly improved after 21 days of treatment; responder status did not predict cognitive changeRuck et al. (2014) \[[@CR57]\]52 MS patients with impaired mobility (only 30 were still on drug after 9--12 months)PASATNo primary endpoint specifiedSignificant improvement on the PASAT after 9--12 months of treatmentBakirtzis et al. (2018) \[[@CR56]\]60 MS patientsBICAMSNo primary endpoint specifiedSignificant improvement on SDMT after 6 months and 1 year of treatment for responders but not non-respondersIGNITE trialPavsic et al. (2015) \[[@CR107]\]30 MS patientsPASATNo primary endpoint specifiedNo significant improvement after 14 or 28 days of treatmentJensen et al. (2014) \[[@CR58]\]105 MS patientsSDMTNoSignificant improvement after 26--28 days of treatment*Donepezil*Greene et al. (2000) \[[@CR108]\]17 MS patients with MMSE ≤ 25 at a long-term care facilityMMSE, HVLTYesSignificant improvement after 4 and 12 weeks of treatment on MMSE and HVLT recognition hits; no differences on HVLT recall trials**Other treatments***Methylprednisolone*Papageorgiou et al. (2007) \[[@CR88]\]18 RRMS patientsComputerized digit spanNoSignificant improvement after 7 days of treatmentStudy authors referred to 'memory performance' in the results table, without specification of what measure they referred to; it is presumably the computerized digit span task that participants completed*Methylprednisolone + cyclophosphamide*Zephir et al. (2005) \[[@CR87]\]28 progressive MS patientsStudy-specific neuropsychological batteryYesSignificant improvement on 4 of 18 measures after 6 months of treatment, and on 6 of 18 measures after 12 months of treatment*BICAMS* Brief International Cognitive Assessment for MS, *HVLT* Hopkins Verbal Learning Test, *MMSE* Mini-Mental State Examination, *MS* multiple sclerosis, *PASAT* Paced Auditory Serial Addition Test, *RRMS* relapsing-remitting multiple sclerosis, *SDMT* Symbol Digit Modalities Test

Disease-Modifying Therapies (DMTs) {#Sec4}
----------------------------------

Disease-modifying therapies are injectable or oral medications designed to prevent relapses and slow down the progression of MS. Various DMTs have different mechanisms of action, but most are immunosuppressive or immunomodulatory.

### Interferon β-1a and Interferon β-1b {#Sec5}

Seventeen studies examined the effects of interferon (IFN) β-1a and IFN β-1b, of which four were RCTs. Two studies compared IFNs β-1a and -1b, four studies examined IFN β-1a only, and 11 studies examined IFN β-1b only. Of 13 non-RCTs, five were class III controlled studies and eight were class IV observational studies. Only eight of all 17 studies investigated cognition as the primary endpoints, of which all but one were class III and IV.

Among studies comparing IFNs β-1a and -1b, one small class II RCT compared two IFN β-1a groups (Avonex and Rebif) with one IFN β-1b group (Betaferon) among 63 relapsing-remitting (RR) MS patients (21 per group) \[[@CR15]\]. The IFN β-1a groups significantly improved on more neuropsychological measures than the IFN β-1b group \[five and six of eight versus one of eight measures on the Brief Repeatable Neuropsychological Battery (BRNB)\] after 1 year of treatment \[[@CR15]\]. However, because the study included more than two primary measures (in fact, there were eight measures), the chances of type I error (i.e. false positive rate) were considerably increased. When we directly calculated and compared the effect sizes of IFN β-1a with IFN β-1b across the five and six statistically significant measures, they were small to negligible (Cohen's *d* = 0.04--0.25 for Avonex, and Cohen's *d* = 0.02--0.36 for Rebif, compared with Betaferon). A class III non-randomized, controlled study found no significant differences between the IFN β-1a and IFN β-1b groups \[[@CR16]\].

In studies evaluating the cognitive effect of IFN β-1a relative to placebo, a class II RCT was conducted among 436 secondary-progressive MS patients, of which researchers of the IMPACT trial found a statistical trend of improvement (small effect: Cohen's *d* = 0.20) on the Paced Auditory Serial Addition Test (PASAT) over 2 years in the treatment group relative to the placebo group \[[@CR17]\]. Of note, although Cohen et al. met all criteria for class I evidence, its classification was designated as class II because cognition was not the sole primary endpoint \[[@CR17]\]. Therefore, these findings would need to be replicated in studies specifically targeting cognition. A class III secondary analysis of a larger RCT found a significant treatment effect \[[@CR18]\], and two class IV observational studies favored high-dose (44 µg) over low-dose (22 µg) IFN β-1a treatment \[[@CR19], [@CR20]\].

In studies examining the cognitive efficacy of IFN β-1b relative to placebo, a class II RCT conducted in 73 primary/transitional progressive MS patients found no significant treatment effect over placebo on the BRNB over 2 years \[[@CR21]\]; however, it was unclear whether allocation was concealed in this study. A class II secondary report of the BENEFIT trial found a significant but small treatment effect (Cohen's *d* = 0.23) for IFN β-1b relative to placebo on the PASAT 2 years after the trial among 439 patients with clinically isolated syndrome \[[@CR22]\]. Since the original BENEFIT trial was not designed to examine cognitive endpoints, these findings would need to be replicated in cognition-focused studies. Apart from observational follow-ups of the two class II RCTs described above, there were three class III studies (one was a secondary analysis of a larger RCT and two were non-randomized, controlled studies), two of which found significant treatment effects \[[@CR23], [@CR24]\]. Of the remaining three class IV observational studies without adequate comparator groups, only one was positive \[[@CR25]\].

In sum, there was no class I evidence for the cognitive efficacy of IFN β-1a or IFN β-1b. Class II RCTs demonstrated small to negligible or no treatment effects. Studies of lower quality yielded mixed findings.

### Glatiramer Acetate {#Sec6}

Seven studies examined the cognitive efficacy of glatiramer acetate. Cognition was not the primary endpoint in any of these studies. Only one study was an RCT (class II), two were class III non-randomized, controlled studies, and four were observational studies without comparator groups. The class II RCT did not detect a significant improvement on the BRNB after 2 years of glatiramer acetate treatment over placebo among 248 RRMS patients \[[@CR26]\]. Since this study was a secondary analysis of an RCT that did not a priori specify cognitive endpoints, it only met criteria for class II. The two class III studies yielded mixed results \[[@CR27], [@CR28]\], and three of four class IV studies were positive \[[@CR29]--[@CR31]\].

### Natalizumab {#Sec7}

There were no prospective RCTs that examined the cognitive efficacy of natalizumab. Five of 13 studies were class III (one was a secondary analysis of a subset of larger RCTs, and four were non-randomized, controlled studies), and the remainder were class IV observational studies without comparator groups. Cognition was the primary endpoint in 8 of 13 studies. The class III secondary analysis of the AFFIRM and SENTINEL RCTs among 942 RRMS patients (subsets of original trials) found a 43% reduced risk of declining 0.5 SDs on the PASAT score 2 years following natalizumab treatment, compared with placebo in the AFFIRM trial \[[@CR32]\]. However, it is important to note that the threshold of 0.5 SDs may not represent a clinically significant decline; studies more typically use at least one SD as the threshold to document change \[[@CR33]\]. Three of four remaining class III studies were positive (of which two studies only found significant effects on one of 10 measures) \[[@CR34]--[@CR36]\]. The eight class IV observational studies without comparator groups were all positive \[[@CR37]--[@CR44]\].

### Fingolimod {#Sec8}

Two studies examined the cognitive efficacy of fingolimod: one class II and one class III. Cognition was not the primary endpoint in either study. A class II pooled analysis of the FREEDOMS and FREEDOMS II RCTs showed significant improvement on the PASAT after the first 6 months of treatment over placebo in 1556 RRMS patients, with a negligible effect size (Cohen's *d* = 0.13) \[[@CR45]\]. The class III open-label (rater-blinded) GOLDEN RCT conducted in 157 cognitively impaired RRMS patients found no significant treatment effect of fingolimod over IFN β-1b after 18 months \[[@CR46]\]. Of note, the authors stated that imbalance in baseline characteristics (i.e. disease severity and baseline cognitive test scores) and dropout pattern may have favored the IFN comparator group.

### Other DMTs {#Sec9}

Additionally, there were one class II, one class III, and two class IV studies for all other DMTs, only one of which was an RCT. Cognition was the primary endpoint in only one of four studies and not in the RCT. The class II RCT, the DECIDE trial conducted in 1841 RRMS patients, found a statistically significant but negligible treatment effect using daclizumab β for 96 weeks compared with IFN β-1a, on the Symbol Digit Modalities Test (SDMT), yielding a negligible effect size (Cohen's *d* = 0.11) \[[@CR47]\]. The study was classified as class II because there was no prespecification of cognitive endpoints in the original trial, as required by AAN criteria. Of note, daclizumab β has been discontinued by pharmaceutical companies due to reports of encephalitis in Europe.

### Summary {#Sec01}

In sum, there is a paucity of good-quality evidence in support of the cognitive efficacy of DMTs in persons with MS. There was no class I evidence for this drug type, and the majority of studies were class III and IV. Class II investigations either showed small/negligible or no significant treatment effects. Although many class III and IV observational studies yielded positive results (particularly for natalizumab), these studies suffered from a myriad of methodological limitations (e.g. absence of randomization or equivalent comparator groups, more than two primary cognitive endpoints), which restricts generalizable validity. Therefore, at this time, there is insufficient evidence to support the use of DMTs to improve cognitive function in persons with MS.

Symptomatic Therapies {#Sec10}
---------------------

Symptomatic therapies may be prescribed for MS patients for specific symptoms, such as mobility or fatigue, as a supplement to DMTs. Given that symptomatic therapies do not target the immunopathology of MS, most studies utilized MS samples of mixed phenotypes.

### Dalfampridine {#Sec11}

Dalfampridine (also known as fampridine or 4-aminopyridine) treats walking difficulties in persons with MS. Twelve studies investigated the cognitive efficacy of dalfampridine, five of which were RCTs: one class I, two class II, and two class III. The remaining seven studies were class IV observational studies without comparator groups. Only 5 of 12 studies investigated cognition as primary endpoints. The class I RCT was conducted with 120 cognitively impaired MS patients \[[@CR48]\]. Significant improvement on the SDMT was observed after 12 weeks of treatment relative to placebo, with a medium effect size (*d* = 0.60). The treatment effect disappeared during a 4-week washout period after the treatment phase. A class II preliminary report of an RCT in 21 RRMS patients found significant improvement after 20 weeks of treatment compared with placebo on only 12 of 35 measures used in this study, with small to medium effect sizes on the significant measures (Cohen's *d* between 0.18 and 0.46) \[[@CR49]\]. The study was limited due to the large number of outcome measures administered without specification of one or two primary outcomes, as required by the AAN criteria. In contrast, another class II RCT did not find a significant treatment effect on the SDMT after 12 weeks among 57 cognitively impaired MS patients \[[@CR50]\]. This study was classified as class II because it did not provide sufficient information regarding its inclusion criteria and randomization. Both class III RCTs used within-subject, crossover designs. Both were class III due to a lack of equivalent treatment order groups at baseline and insufficient examination or accounting for carryover effects. One of the class III studies, the FAMPKIN extension trial, consisted of a 2-year observational period (when the whole sample received treatment) followed by a crossover RCT phase \[[@CR51]\]. Only 20 of 32 patients from the extension trial completed the RCT phase, during which cognitive performance was superior during the dalfampridine condition compared with the placebo condition, on only one of eight measures. The other class III crossover RCT in 20 MS patients found no significant cognitive improvement during the 2-week treatment condition relative to the placebo condition \[[@CR52]\]. Of the remaining seven class IV observational studies, six were positive \[[@CR53]--[@CR58]\].

In sum, there was one class I study in support for the cognitive efficacy of dalfampridine, with a medium effect size. For the remaining studies, higher-quality works (class II and III RCTs) yielded mixed results, while lesser quality class IV observational investigations were more likely to be positive. Thus, more work needs to be done to confirm the results of the one class I study for dalfampridine.

### Cognition-Enhancing Medications {#Sec12}

Cognition-enhancing medications include dementia medications (e.g. for Alzheimer's disease) and supplements purporting cognitive benefit (e.g. *Gingko biloba*). Although some stimulants are used to improve cognition \[e.g. for attention-deficit/hyperactivity disorder (ADHD)\], they are not included in this section because they are subsumed under the category of 'Stimulants' in Sect. [3.2.3](#Sec13){ref-type="sec"}, along with other stimulants that are typically prescribed for wakefulness (e.g. for narcolepsy and fatigue). Nine studies on dementia medications were identified: seven studies for cholinesterase inhibitors (three for donepezil and four for rivastigmine) and two studies for memantine, an *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor antagonist. Three studies on *Gingko biloba* were also included. All but three studies (two were neuroimaging studies involving rivastigmine and one examined *Gingko biloba*) studied cognition as primary endpoints.

Two class I RCTs and one class IV observational study examined donepezil. Both class I RCTs were conducted by the same research group, who started with a smaller single-center trial followed by a larger multicenter trial to confirm previous results. In the smaller trial among 68 mildly cognitively impaired MS patients, significant improvement was observed on the Selective Reminding Test (SRT) after 24 weeks of donepezil treatment relative to placebo with a medium effect size (Cohen's *d* = 0.49) \[[@CR59]\]. However, the larger RCT of 120 mildly cognitively impaired MS patients did not show a significant donepezil treatment effect compared with placebo \[[@CR60]\], and therefore did not confirm previous results.

Four RCTs examined rivastigmine: one class I, two class II, and one class III. The class I RCT on 60 mildly cognitively impaired MS patients found no significant treatment effect, relative to placebo, on the Wechsler Memory Scale (WMS) general memory score after 12 weeks \[[@CR61]\]. One of the class II RCTs was a small functional magnetic resonance imaging (fMRI) study with 15 MS patients \[[@CR62]\]. Those researchers found a significant but small treatment effect on the modified PASAT after a single dose of rivastigmine compared with placebo (Cohen's *d* = 0.25). The study was classified as class II due to the lack of specification of primary endpoints. The other class II RCT had a larger sample size with 81 cognitively impaired MS patients, but did not find a significant treatment effect for rivastigmine over placebo on the SRT after 16 weeks \[[@CR63]\]. The last class III RCT was also an fMRI study and did not detect a significant treatment effect on the BRNB in a single (investigator)-blind, crossover design among 15 MS patients \[[@CR64]\]. In sum, three of four RCTs (including a class I study) did not find significant cognitive treatment effects for rivastigmine among persons with MS.

One class II and one class III RCT examined memantine. Both studies used samples of mildly cognitively impaired MS patients (114 and 62, respectively) and found no significant treatment effect for memantine over placebo on the PASAT after 16 and 52 weeks \[[@CR65], [@CR66]\].

Two class II and one class III RCT examined *Gingko biloba*. All three studies specified more than two primary endpoints, which violated AAN class I criteria. The class II studies conducted in 38 and 120 cognitively impaired MS patients found no significant treatment effects relative to placebo after 12 weeks \[[@CR67], [@CR68]\]. A class III pilot RCT found medium to large treatment effects compared with placebo among 21 MS patients, on only two measures (Cohen's *d* = 0.55 for the Visual Threshold Serial Addition Test, and *d* = 0.78 for the California Verbal Learning Test (CVLT) intrusions) out of a large number of measures (total number of measures unspecified) \[[@CR69]\], with an inflated type I error rate.

In sum, there was consistently high-quality evidence (class I and II) that cognition-enhancing medications used for dementia (e.g. donepezil, rivastigmine, memantine) and *Gingko biloba* did not have a positive treatment effect in individuals with MS.

### Stimulants {#Sec13}

Nine studies investigated the cognitive efficacy of central nervous system stimulants: three on [l]{.smallcaps}-amphetamine sulfate, one on methylphenidate, one on lisdexamfetamine dimesylate, one on mixed amphetamine salts, one on armodafinil, and two on modafinil. Amphetamine-based stimulants and methylphenidate are typically prescribed to treat inattention for individuals with ADHD, and modafinil/armodafinil are used to treat fatigue in persons with MS (as well as narcolepsy). All but two studies (both for modafinil) examined cognition as the primary endpoint.

[l]{.smallcaps}-Amphetamine sulfate was investigated in one class I, one class II, and one class III study. In the class I RCT among 136 cognitively impaired MS patients, no significant treatment effect relative to placebo was found after 29 days, on the primary endpoint SDMT, an information processing speed measure \[[@CR70]\]. A class II post hoc reanalysis of this trial divided patients based on baseline memory impairment (median split) \[[@CR71]\]. Significant and large treatment effects for [l]{.smallcaps}-amphetamine compared with placebo were found on the CVLT-II and the Brief Visual Memory Test-Revised (BVMT-R) delayed recall scores (Cohen's *d* = 0.94 for CVLT-II and *d* = 1.00 for BVMT-R), but only among individuals with memory impairment at baseline. In contrast, a preliminary class III crossover RCT among 19 cognitively impaired MS patients found significant medium-size treatment effects for a single dose of [l]{.smallcaps}-amphetamine 45 mg relative to placebo on information processing speed measures \[PASAT, SDMT, and part A of the Trail-Making Test (Cohen's *d* = 0.36--0.45)\]; there was no significant change on memory measures \[[@CR72]\]. Lower doses of [l]{.smallcaps}-amphetamine (15 or 30 mg) were not found to be more efficacious in improving cognitive function than placebo in this study. Still, the investigation by Benedict et al. was limited in its lack of specification of primary cognitive measures, as well as failure to examine crossover effects or baseline equivalency of treatment order groups \[[@CR72]\]. Efficacy of a single dose of mixed amphetamine salts was investigated in a class I RCT among 49 cognitively impaired MS patients \[[@CR73]\]. Significant improvement on the SDMT was evidenced in the treatment group relative to placebo, with a medium effect size (Cohen's *d* = 0.47). No significant change was observed on the PASAT, the other primary endpoint. A class II RCT examined lisdexamfetamine dimesylate within a sample of 63 cognitively impaired MS patients \[[@CR74]\]. Significant improvement on the SDMT was observed after 4 weeks of treatment up to the highest tolerable dose compared with placebo, with a medium effect size (Cohen's *d* = 0.62). The improvement on SDMT was maintained for another 4 weeks of treatment. Again, no significant improvement was observed on the other primary endpoint, the PASAT. Of note, 76% of enrolled participants prematurely dropped out of this trial, which increased bias in the final results. A smaller class II RCT examined methylphenidate in 26 low average to cognitively impaired RRMS patients \[[@CR75]\]. They found significant improvement on the PASAT after a single dose of the medication compared with placebo. Effect sizes were medium and large (Cohen's *d* = 0.52 for the three-second trial and 0.71 for the two-second trial). Limited details regarding randomization and blinding were presented in this paper.

In sum, there were contradictory class I findings with regard to the cognitive efficacy of amphetamine-based formulations; two RCTs (class II and III) reported significant treatment effects. Methylphenidate and lisdexamfetamine dimesylate each had a single RCT demonstrating their efficacies (none of which were class I).

Three class II RCTs and one class III secondary analysis of a larger RCT investigated modafinil and armodafinil. The larger class II RCT conducted with 121 fatigued MS patients showed contradictory findings after 8 weeks, favoring the modafinil group on the SDMT and favoring the placebo group on the PASAT \[[@CR76]\]. The study was limited in its lack of detailed account of blinding. Both of the smaller class II RCTs were within-subject, crossover designs and utilized samples of cognitively impaired MS patients: 30 patients taking armodafinil and 16 patients taking modafinil \[[@CR77], [@CR78]\]. Both studies found a significant treatment effect on only one of multiple measures (8 and 11, respectively); one of the significant findings was on a predefined secondary endpoint and not a primary endpoint; therefore, probabilities for type I error were high. A class III secondary analysis of a larger RCT observed a significant treatment effect \[[@CR79]\].

### Other Symptomatic Therapies {#Sec14}

Amantadine is also used to treat fatigue in persons with MS. Two class III studies (one was a prospective crossover RCT and one was secondary analysis of a larger RCT) examined amantadine in 24 \[[@CR80]\] and 45 fatigued MS patients \[[@CR81]\]. Cognition was not the primary endpoint in either study. Neither study found significant treatment effects compared with placebo after 10 days and 6 weeks, respectively.

### Summary {#Sec02}

In sum, contrary to studies on DMTs, most studies on symptomatic therapies were RCTs and examined cognition as primary endpoints (see Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). They also tended to use samples of cognitively impaired patients, increasing sensitivity. Furthermore, symptomatic therapies generally yielded stronger treatment effect sizes (medium range) than DMTs (small to negligible) in RCTs that yielded positive findings (see Fig. [5](#Fig5){ref-type="fig"}). However, conclusions were difficult to draw because there were many contradictory findings in these RCTs (negative findings were not illustrated in Fig. [5](#Fig5){ref-type="fig"}). The best evidence was in dalfampridine, with one class I RCT in support of its cognitive efficacy and a medium treatment effect size. However, multiple lower-quality RCTs yielded mixed findings for dalfampridine. In contrast, there was quality evidence (class I and II) that demonstrated no significant treatment effects for cognition using dementia medications (e.g. donepezil, rivastigmine, memantine) or *Gingko biloba*. Lastly, other symptomatic therapies yielded largely mixed results in terms of their cognitive efficacy. Thus, overall, there is insufficient evidence at this time to support the use of symptomatic therapies to improve cognitive function in persons with MS.Fig. 3Summary of studies based on **A** study type and **B** AAN class of evidence. For disease-modifying therapies, the number of studies increased as the quality of evidence decreased. For symptomatic therapies, the majority of studies were randomized controlled trials, and AAN classification levels were evenly distributed. *AAN* American Academy of NeurologyFig. 4Proportion of cognition-focused studies, stratified by medication and study type. For disease-modifying therapies, more than half of the studies did not specify cognition as the primary endpoint. For symptomatic therapies, most studies examined cognition as the primary endpoint and these studies tended to be higher in quality compared with other medication typesFig. 5Summary of effect sizes in RCTs based on medication type. Effect sizes are expressed as Cohen's *d*. Weighted effect size = ratio of positive measures to total measures × effect size. Only positive RCTs are included (*n* = 20). Additionally, there were three positive RCTs with insufficient data to calculate Cohen's *d*, and 18 negative RCTs. On average, effect sizes for disease-modifying therapies were negligible, and effect sizes for symptomatic therapies were in the medium range. *RCTs* randomized controlled trials

Other Therapies {#Sec15}
---------------

This section includes medications that are not DMTs and do not target a specific MS symptom (e.g. ambulatory disability, cognition). Cognition was not the sole primary endpoint in any of these studies. Two studies examined recombinant human erythropoietin (EPO): one class II and one class IV. The class II RCT among 50 progressive MS patients found no significant treatment effect after 24 weeks of high-dose EPO treatment on part B of the Trail-Making Test \[[@CR82]\]. Schreiber et al. \[[@CR82]\] did not specify cognition as the sole primary endpoint, and it was therefore classified as class II. Two class II RCTs examined statins for 24 months and provided limited or no evidence for their cognitive efficacy. One study found significant improvement using simvastatin over placebo on one screening measure of 15 total measures among 140 secondary-progressive MS patients; primary endpoints were not specified in this study \[[@CR83]\]. The other study did not find a significant treatment effect using atorvastatin among 154 RRMS patients; there was a high dropout rate and only 63% of enrolled participants were part of the final analyses \[[@CR84]\]. A class II RCT compared high- and low-dose estrogen as supplemental therapy for IFN β-1a in 142 female RRMS patients \[[@CR85]\]. After 24 months, the high-dose estrogen group (estrogen + IFN) included significantly fewer patients with cognitive impairment than the no-estrogen group (IFN only) and lower risk of developing cognitive impairment (high-dose vs. no-estrogen, odds ratio 0.27). Low-dose estrogen did not have a significant treatment effect. Classification as class II was due to the lack of a primary endpoint specification. Three studies examined methylprednisolone: one class III non-randomized, quasi-controlled study \[[@CR86]\] and two class IV observational studies all found significant treatment effects \[[@CR87], [@CR88]\], but there were no class I or II studies to establish generalizable validity.

In sum, there was limited quality evidence to support the cognitive efficacy of medications reviewed in this section, and therefore insufficient evidence to support their use to improve cognitive function in persons with MS at this time.

Discussion {#Sec16}
==========

The current review aimed to systematically evaluate the cognitive efficacy of pharmacologic treatments for MS (including disease-modifying, symptomatic, and other therapies) based on papers published in peer-reviewed journals between 1990 and January 2020. Overall, none of the medications reviewed yielded consistently positive, high-quality evidence in support for their cognitive efficacy, which is in line with the most recent Cochrane review \[[@CR9]\]. The best evidence was in dalfampridine, with one class I RCT that found a medium-sized treatment effect. However, other RCTs with dalfampridine of lower classifications yielded largely mixed findings. In contrast, there was consistently high-quality evidence (class I and II) that cognition-enhancing medications used for dementia (e.g. donepezil, rivastigmine, memantine), and *Gingko biloba*, did not have a positive treatment effect in individuals with MS. One notable finding in this review was that overall, lower-quality observational studies (i.e. class III quasi-controlled studies or class IV uncontrolled studies) tended to yield more positive findings than higher-quality studies (i.e. RCTs), as illustrated in Fig. [2](#Fig2){ref-type="fig"}. Focus on lower-quality studies may give clinicians a biased impression of the overall literature base. Furthermore, due to the scarcity of research, optimal dosage and treatment duration for the medications reviewed are unknown as existing studies vary in dosage and treatment intervals. Therefore, much work (e.g. higher-quality RCTs, comparisons of different dosages and treatment duration) is needed before formal recommendations can be made about any of the medications reviewed. We recommend future clinical trial researchers guide their research designs using standardized criteria, such as the AAN criteria, to ensure minimization of bias.

Interestingly, there was no quality evidence demonstrating cognitive efficacy for DMTs, the gold-standard treatment for MS. In fact, from our review, there were no class I studies, and class II and III studies either demonstrated no treatment effect or yielded small to negligible effect sizes. Furthermore, few good-quality studies on DMTs focused on cognition as a primary endpoint, compared with symptomatic therapies, which limited the validity and generalizability of positive findings. Additional high-quality, cognition-focused investigations of DMTs should be conducted, given the pervasiveness and insidious impact of cognitive impairment among persons with MS \[[@CR1], [@CR2], [@CR89]\]. Cognition-focused investigations would allow researchers to consider cognition-related factors in study design and analysis, and calculate power based on the cognitive outcomes. For example, to increase sensitivity for a particular cognitive treatment, it may be advantageous to recruit only cognitively impaired individuals. This was done in studies of most of the symptomatic medications (but not DMTs), as the primary goal in these studies was to evaluate cognitive benefit. Therefore, unsurprisingly, most symptomatic therapy investigations were generally higher quality (e.g. RCTs with multiple class I studies) than DMT investigations. That being said, there were many contradictory findings for symptomatic treatments. Additional inquiries into moderating treatment response variables may help explain the mixed results.

One reason for the mixed results pervasive in this review may be the heterogeneity of cognitive assessment procedures. Some studies used single primary endpoints, some used consensus batteries for MS (e.g. BRNB), and others used study-specific batteries of neuropsychological tests. Studies utilizing a battery of tests (without specification of one or two primary endpoints) may find statistically significant effects in a subset of the tests administered, and the number of significant measures may vary among studies, resulting in difficulty in interpretation (i.e. how many significant tests in a battery signify an overall positive study?). However, strictly adhering to AAN criterion of including only one or two primary endpoints (meant to reduce type I error) presents its own challenges for cognition-focused investigations. There is not a single 'gold standard' neuropsychological test. In fact, performance variability within a battery of neuropsychological tests occurs in even cognitively healthy individuals, with a difference of as much as six SDs between the highest and lowest scores \[[@CR90]\]. In the MS literature, there is increasing consensus to use the SDMT as the standard primary endpoint in clinical trials \[[@CR91]\]. Although the SDMT measures the most prevalent cognitive deficit in MS, i.e. information processing speed, it does not account for impairment in other cognitive domains, such as learning and memory or executive functions (in which impairments are also common among persons with MS). Therefore, guidelines regarding best practice in selecting primary cognitive endpoints for clinical trials, considering the aforementioned issues, is warranted. Nevertheless, future studies should prespecify primary endpoints in order to minimize type I error, in accordance with the AAN criteria.

A systemic problem identified in the current review (and research studies in general) is the overreliance on statistical significance using the *p* value. Indeed, the present review revealed that in studies (some high in quality) that found statistically significant effects (with *p* values below the conventional 0.05 threshold; most studies do not adjust for multiple comparisons), some studies yielded small or even negligible effect sizes (Cohen's *d* \< 0.20). Overreliance on the *p* value has been cited as one of the reasons for the reproducibility crisis. Furthermore, a statement from the American Statistical Association stressed that the *p* value does not measure the size of an effect or the significance of a finding \[[@CR92]\]. Instead, statisticians recommend using effect sizes, and confidence intervals around the effect sizes, to denote the significance of a result \[[@CR93], [@CR94]\]. Therefore, when evaluating whether to prescribe a certain medication to improve cognitive function in MS patients based on published findings, clinicians are urged to consider the effect sizes and confidence intervals rather than reliance on the *p* values.

The current review offers unique strengths compared with past reviews on the same topic. The inclusion of a standardized effect size measure provides an objective metric that can be compared across studies. The use of evidence classification helps to account for potential sources of bias in the studies reviewed. However, a few limitations have to be addressed. We only calculated effect sizes for positive findings in controlled studies. It is possible that some negative studies have strong effect sizes but did not reach statistical significance due to small sample sizes. We decided to not calculate effect sizes for negative findings because one could argue that small sample sizes may not be representative samples of the population being investigated. Nevertheless, we note this as a limitation, as it may underestimate the overall effects observed in the literature. Furthermore, we were unable to calculate effect sizes for some studies due to insufficient data, such as missing means and SDs. Due to these missing data, along with variability in the study endpoints, we were unable to conduct a quantitative meta-analysis. Another limitation of our effect size calculations is the treatment of all available data as a parametric. Although some studies utilized non-parametric tests for their main analyses, the majority did not provide the relevant statistics for which effect sizes could be calculated. Thus, we used the provided means and SDs to calculate Cohen's *d*. Lastly, we did not account for correlations between repeated measurements in our effect size calculations because most studies did not provide this information.

Conclusions {#Sec17}
===========

According to the current systematic review, there is insufficient evidence to support the use of pharmacologic treatments to improve cognitive function in persons with MS. There were many contradictory findings observed in this review, which may be due to possible unidentified moderating treatment response variables and/or lack of standardization in assessment procedures. Higher-quality RCTs with cognition as the primary outcome are needed to establish the cognitive efficacy of pharmacologic treatments for MS-related cognitive dysfunction. Future clinical trial researchers are urged to utilize standardized criteria (such as the AAN criteria) to guide their study designs. There was also an overreliance on statistical significance in determining the overall cognitive efficacy of a medication, which may not be clinically meaningful. Clinicians should consider effect sizes of medications before deciding whether to prescribe them to ameliorate cognitive symptoms.
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